Side Effect Profiles of Selective Serotonin Reuptake Inhibitors: A Cross-Sectional Study in a Naturalistic Setting

N. A. Uvais, MBBS, DPM; P. Shihabudheen, MD; K. Anagha, MPharm; T. Shafeena, MPharm

Prim Care Companion CNS Disord 2021;23(4):20m02747

ABSTRACT

Background: Side effects of selective serotonin reuptake inhibitors (SSRIs), the most commonly used antidepressants, are usually underreported in clinical trials. Systematic evaluation of side effects associated with SSRIs with structured instruments in a naturalistic setting is an important design to fully understand the side effect profile of various SSRIs. We examined the frequencies of the side effects induced by 3 commonly used SSRIs, sertraline, escitalopram, and fluoxetine, by using a self-rating instrument designed to measure the subjective symptoms of patients in a naturalistic treatment setting.

Methods: The subjects were outpatients recruited from the psychiatry department of a tertiary care hospital. The subjects were aged ≥ 18 years; were diagnosed with depression, anxiety spectrum disorders, adjustment disorder, hypochondriasis, or impulse control disorder according to ICD-10 criteria; and were on SSRI monotherapy. The assessment instrument included 42 items and was devised using drug package insert data on the most commonly observed side effects of antidepressants released by the US Food and Drug Administration.

Results: A total of 100 patients participated in the study. Among them, 70% were women. The most common diagnosis was depression (49%). Of the patients, 53% were taking sertraline, 38% escitalopram, and 8% fluoxetine. The common side effects reported by patients were flatulence (64%), somnolence (59%), memory impairment (51%), decreased concentration (50%), yawning (47%), fatigue (45%), dry mouth (45%), weight gain (45%), light headedness (43%), and sweating (38%). Patients treated with escitalopram had significantly higher incidence of headache, pruritus, memory impairment, decreased concentration, and dizziness. Patients treated with sertraline had significantly decreased appetite.

Conclusions: The study results highlight the prevalence and pattern of side effect profiles of 3 commonly used SSRIs and provide baseline data for comparison with other similar studies.

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (24)

Chae JH, Lee KU, Shin YK, et al. Comparison of side effect profiles between mirtazapine and selective serotonin reuptake inhibitors; a naturalistic setting. Clin Psychopharmacol Neurosci. 2004;2:31–35.
Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22–27. PubMed CrossRef
Rief W, Nestoriuc Y, von Lilienfeld-Toal A, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf. 2009;32(11):1041–1056. PubMed CrossRef
Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf. 2008;31(10):851–865. PubMed CrossRef
Bet PM, Hugtenburg JG, Penninx BW, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–1451. PubMed CrossRef
Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164–172. PubMed CrossRef
Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(suppl 4):4–11, discussion 12–13. PubMed
Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009;6(2):16–18. PubMed
Janssen P, Vos R, Tack J. The influence of citalopram on interdigestive gastrointestinal motility in man. Aliment Pharmacol Ther. 2010;32(2):289–295. PubMed CrossRef
Browning KN. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Front Neurosci. 2015;9:413. PubMed CrossRef
Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999;20(3):277–287. PubMed CrossRef
Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270–288. PubMed CrossRef
Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders, III: tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12(suppl B):S55–S87. PubMed CrossRef
Sayyah M, Eslami K, AlaiShehni S, et al. Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. Psychiatry J. 2016;2016:5480391. PubMed CrossRef
Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28(1):32–72. PubMed CrossRef
Wichniak A, Wierzbicka A, Walęcka M, et al. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017;19(9):63. PubMed CrossRef
Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol. 2002;17(suppl 1):S27–S32. PubMed CrossRef
Safa M, Sadr S, Talischi F, et al. Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder. Ther Adv Psychopharmacol. 2013;3(6):306–313. PubMed CrossRef
Herizchi S, Mogaddam A. Comparison of citalopram and fluoxetine sexual side-effects in male patients referred to psychiatric clinic. J Anal Res Clin Med. 2016;4(4):221–227. CrossRef
Montejo AL, Llorca G, Izquierdo JA. Sexual dysfunction with SSRIs: a comparative analysis. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association (abstract NR717.266); May 9, 1996; New York, NY.
Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014;37(1):19–31. PubMed CrossRef
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259–1272. PubMed CrossRef
Arterburn D, Sofer T, Boudreau DM, et al. Long-term weight change after initiating second-generation antidepressants. J Clin Med. 2016;5(4):E48. PubMed CrossRef
Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;361:k1951. PubMed CrossRef